TEI Biosciences Inc.
Division of Integra LifeSciences Holdings Corp.
Latest From TEI Biosciences Inc.
Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
With worldwide revenues projected to reach $6 billion in 2015, mega-deals and innovative game-changing technologies have transformed the advanced wound care market into a robust, high-tech arena in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Tissue Engineering Inc.
- North America
- Parent & Subsidiaries
- Integra LifeSciences Holdings Corp.
- Senior Management
Yiannis Monovoukas, PhD, Chmn., Pres. & CEO
Bret Jessee, PhD, VP, New Product Dev.
Eric Newman, Dir., Fin.
Raoul Verheggen, Dir., Mktg.
- Contact Info
TEI Biosciences Inc.
Phone: (617) 268-1616
1000 Winter St.
Waltham, MA 02451
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.